Medical breakthroughs missed because of pointless drug bans

Vx3mkwtp-1370889557 

“In 1632 the Catholic Church convened a case against Galileo on the grounds that his work using the telescope to explore the nature of the heavens contradicted the church’s teaching – the culmination of a long fight that had lasted 16 years.

Galileo was put under house arrest and his research stopped. Some of his inquisitors refused even to look down a telescope, believing it to be the work of the devil. With his life under threat, Galileo retracted his claims that the earth moved around the sun and was not the centre of the universe. A ban by the papal Congregation of the Index on all books advocating the Copernican system of planetary motion – which we use today – was not revoked until 1758.

Three centuries later we have an equivalent case of scientific censorship. In the 1960s and the 1970s the UN effectively banned a whole range of drugs from cannabis, opioids and cocaine through to psychedelics – LSD and “magic mushrooms”. They did this in a futile attempt to reduce the use and harms of these drugs, but both consumption and harms have increased ten-fold since then, and many of the negative effects of these laws include the rise of AIDS and the collapse of law and order in Mexico.

However, another major impact of these laws – restriction of research – has hardly been discussed. Yet this is arguably as significant a problem and must change.

A research black hole

Two of the most limiting areas have been in the fields of research into cannabis and psychedelics, both of which were put into the UN’s most restrictive lists, deemed to have no value to medicine.

Currently in the UK to work with these compounds you need a special licence, which along with additional police checks, costs more than £5000 and takes a year to get. In the UK only three hospitals have these, making clinical research almost impossible. Contrast this with the situation for heroin, a much more abused and harmful drug, which can be held by any hospital with a license.

The field of research that has been most censored is that of psychedelics (LSD and psilocybin) and empathogens (MDMA and Ecstasy).

Before the LSD ban there were more than 1000 publications on its therapeutic potential – its hallucinogenic properties undiscovered until five years after its discovery in 1938. Since then there have been none – despite its proven utility in disorders including alcoholism, end of life suffering and cancer pain.

The ban was largely driven by political concerns. Despite being justified by claims of harm such as people dying while trying to fly, its use was also discouraging young people in the US fighting in the Vietnam war.

The psychedelic state is also one of the most intriguing kinds of brain function that can illuminate the fundamental mechanisms of the brain and give us novel insights into consciousness.

Drugs such as MDMA can help conditions such as post traumatic stress disorder.

The banning of cannabis was purely political. It was already being used as a medicine in many countries before it was banned. With the notable exception of The Netherlands, most countries agreed to this dishonest change in status. In the UK, it has criminalised many patients with incurable conditions such as multiple sclerosis who could benefit from the drug.

But it has also led to a severe impairment of medical research into the cannabis plant. There are more than 50 active chemicals in the cannabis plant and many of these were discovered in the UK. However, turning any of these into medicines is very slow due to unnecessarily tough regulations. This has set back UK leadership in the field and wasted huge economic opportunities.

Basic neuroscience research has also been held back. Cannabis works on cannabinoid receptors in the brain – and we have a lot of these – surprisingly more than our dopamine (pleasure and reward) and serotonin receptors (wellbeing and happiness) combined. Cannabinoid receptors do many things and are involved in learning and memory, eating and sleep anxiety.

Their role is therefore of great interest but studying them requires working with compounds such as THC (the element of cannabis that makes people stoned). But again, the regulations make getting these expensive and difficult.

Time to challenge outdated controls

What can be done? It’s very easy once we accept that no meaningful benefits come from controls that have been left unchallenged for 50 years. In the UK we can exempt hospitals from the need to have the licences – they could hold cannabis safely alongside heroin. We can also exempt very small amounts of the drugs (below a clinically meaningful dose for example) from any control at all, so that scientists doing basic research can work without hindrance.

The transfer of small amounts of test compounds between different countries should also be exempt from import and export rules that now apply to every compound on a case-by-case basis – which also significantly impairs detection of new “legal highs” because samples can’t easily be shared across Europe.

Ideally, a fundamental change in the world perspective should also happen. The UN conventions are outmoded and should be fully revised. This can happen at the 2016 UN General Assembly Special Session (UNGASS) meeting into drug control – the first opportunity to do so in some time.

In the meantime, let’s get scientists as well as patient and civil liberty groups working together to achieve this. We need more petitions. We need more leadership. Some countries are already showing this. New Zealand is beginning to change where it stands on legal highs with the Psychoactive Substances Bill. Some South American countries are also now taking a more rational approach. What we need to do now is put science at the forefront of research.”

-David Nutt

http://theconversation.com/medical-breakthroughs-missed-because-of-pointless-drug-bans-15072

Forbidden Medicine – WebMD

“Laws and medicine clash over medicinal marijuana use. If it weren’t for his few daily tokes from marijuana cigarettes, Kiyoshi Kuromiya believes he would no longer be alive.The Philadelphia AIDS patient and activist had lost 40 pounds over a four-month period and spent most days nauseated before he began smoking pot in 1995 to boost an appetite suppressed by his disease.”Marijuana saved my life,” says Kuromiya, 57, who was diagnosed with AIDS in 1988. “It’s a great irony to me that I can buy cigarettes, which will kill me, anywhere. But marijuana, which has kept me breathing, is illegal.”Kuromiya and others with debilitating ailments have long argued that marijuana should be legally available when standard medical treatment can’t relieve a patient’s suffering and pain.”

More: http://www.webmd.com/a-to-z-guides/features/forbidden-medicine

Medical Cannabis Use Doesn’t Adversely Impact Substance Abuse Treatment Outcomes, Study Says

“The physician-supervised use of medical marijuana does not adversely affect the outcomes of individuals enrolled in substance abuse treatment programs, according to clinical trial data published last week in the Harm Reduction Journal.

An investigator at Humboldt State University in California assessed whether medical cannabis use was associated with negative outcomes in patients referred to a substance abuse treatment program.

The study reported that treatment outcomes for medically authorized cannabis users were comparable to those of subjects who were not supervised to use the drug.

“Cannabis use did not seem to compromise substance abuse treatment amongst the medical marijuana using group, who (based on these preliminary data) fared equal to or better than non-medical marijuana users in several important outcome categories (e.g., treatment completion, criminal justice involvement, medical concerns),” the study concluded. “This exploratory study suggests that medical marijuana … may not adversely affect positive treatment outcomes.””

http://norml.org/news/2010/03/19/medical-cannabis-use-doesn-t-adversely-impact-substance-abuse-treatment-outcomes-study-says

“Medical marijuana users in substance abuse treatment” Full Text: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2848643/

Even More Science Suggesting That Cannabinoids May Halt Diabetes

“Preclinical study data published online in the scientific journal Nutrition & Diabetes reports that tetrahydrocannabivarin (THCV) — a naturally occurring analogue of THC — possesses positive metabolic effects in animal models of obesity.

British researchers assessed the effects of THCV administration on dietary-induced and genetically modified obese mice. Authors reported that although THCV administration did not significantly affect food intake or body weight gain in any of the models, it did produce several metabolically beneficial effects, including reduced glucose intolerance, improved glucose tolerance, improved liver triglyceride levels, and increased insulin sensitivity.

Researchers concluded: “Based on these data, it can be suggested that THCV may be useful for the treatment of the metabolic syndrome and/or type 2 diabetes (adult onset diabetes), either alone or in combination with existing treatments. Given the reported benefits of another non-THC cannabinoid, CBD in type 1 diabetes, a CBD/THCV combination may be beneficial for different types of diabetes mellitus.””

More: http://beforeitsnews.com/marijuana-debate/2013/06/even-more-science-suggesting-that-cannabinoids-may-halt-diabetes-2444932.html

Looking at Cannabis Based Type 2 Treatment

“One of the classic effects of cannabis on people is raging hunger-the “marijuana munchies.” The drug has been used to good effect on people with diseases that diminish appetite, helping them to regain a healthy interest in food. So it is a bit ironic that British drug maker GW Pharmaceuticals has created a cross-bred cannabis plant whose appetite-suppressing qualities could be used to treat type 2 diabetes.”

 
“The new strain contains an appetite-suppressing compound called THCV (tetrahydrocannabivarin), a cannabinoid* found in cannabis sativa-marijuana. The company sees a drug that uses THCV as potentially useful in helping type 2s and obese people control their appetites-a key to good blood sugar control.

In 2010, GW introduced a cannabis-based drug to treat the symptoms of multiple sclerosis. Already, the company has found 60 cannabinoids in the cannabis sativa plant. A company spokesman says that only 12 to 15 of them have been explored in any depth.

*Cannabinoids are the active ingredients in cannabis sativa that create the plant’s physical and mental effects when it is ingested or smoked.”

http://diabeteshealth.com/read/2011/06/30/7200/looking-at-cannabis-based-type-2-treatment/

Medicinal marijuana stops seizures, brings hope to a little girl – NBC

“Six-year-old Charlotte Figi, a picture of precious in her “Gatsby”-style bob and blue toenails, stands patiently as her mother reaches up her dress to change her out of her soiled Pull-Ups.”

Read more on Colorado Springs Gazette

http://www.nbcnews.com/id/52147512/ns/local_news-colorado_springs_co/t/medicinal-marijuana-stops-seizures-brings-hope-little-girl/

‘Milestone’ epilepsy drug based on cannabis

A collaboration between a UK research team and international medicine manufacturers may lead to a ‘milestone’ treatment for epilepsy. This treatment appears more bearable than current epilepsy medicines – and is based on cannabis.

A research team at the University of Reading performed the research, which was recently published in The British Journal of Pharmacology. Their research explored the use of cannibidivarin – a natural chemical called a ‘cannabinoid’ from the cannabis plant.

Cannibidivarin does not have psychoactive properties (anyone taking a drug based on this chemical will not feel ‘high’ as a result). It appears to reduce seizure frequency in laboratory animals with epilepsy and has fewer side-effects than traditional epilepsy medicines. The new drug can also be safely combined with regular medications.

Lead study author, Dr Ben Whalley, said: “This is an enormously exciting milestone in our investigations into non-psychoactive elements of cannabis as treatments for epilepsy. Our work has highlighted the potential for a solution based on cannabinoid science. It has shown that cannabidivarin is the most effective and best tolerated anticonvulsant plant cannabinoid investigated to date.””

More: http://www.epilepsy.org.uk/news/news/%E2%80%98milestone%E2%80%99-epilepsy-drug-based-cannabis

Marijuana and its receptor protein in brain control epilepsy

“VCU study is first to test anticonvulsant potential of marijuana and brain recurrent seizures. 

Ingredients in marijuana and the cannabinoid receptor protein produced naturally in the body to regulate the central nervous system and other bodily functions play a critical role in controlling spontaneous seizures in epilepsy, according to a new study by researchers at Virginia Commonwealth University.

The study, the first to look at marijuana and the brain’s cannabinoid system in live animals with spontaneous, recurrent seizures, suggests new avenues that researchers can explore in their search for more-effective drugs to treat epileptic patients who don’t respond to today’s anticonvulsant medications or surgery.

The results appear in the Oct. 1 issue of the Journal of Pharmacology and Experimental Therapeutics.

“Although marijuana is illegal in the United States, individuals both here and abroad report that marijuana has been therapeutic for them in the treatment of a variety of ailments, including epilepsy,” says Dr. Robert J. DeLorenzo, professor of neurology in the VCU School of Medicine.

 “If we can understand how marijuana works to end seizures, we may be able to develop novel drugs that might do a better job of treating epileptic seizures.” 

Epilepsy is one of the most common neurological conditions, characterized by spontaneously recurrent seizures. Approximately 1 percent of Americans have epilepsy, and 30 percent of those patients are resistant to conventional anticonvulsant drug treatments.

Cannabinoids have been used as a natural remedy for seizures for thousands of years, and studies since at least 1974 have found that the primary psychoactive compound in marijuana displays anticonvulsant properties.” 

More:http://www.news.vcu.edu/news/Marijuana_and_its_receptor_protein_in_brain_control_epilepsy

Medical marijuana helps stem 6-year-old’s seizures – CNN

“Six-year-old Jayden David violently shakes on the ground, his blue eyes vacant and then filled with searing pain. The video shows an unvarnished look at a seizure, something Jayden once experienced routinely.

Not anymore, says his father, thanks to medical marijuana.

Before he started taking a liquid, nonpsychoactive form of marijuana, Jayden couldn’t walk, eat solid food or take a bath.

He has Dravet’s syndrome, a rare and catastrophic form of childhood epilepsy. It has triggered seizures so frequent that 44 times he has been rushed to the hospital in an ambulance, his distraught father by his side.

Jayden’s doctors prescribed 22 anti-seizure pills a day, which controlled the seizures but left him immobilized due to the side effects.

“He’s in pain and suffering and crying,” said Jayden’s father, Jason David. “You can’t help him no matter what. What are you supposed to do? You have to do whatever it takes to save their life.”

Last year, he had enough. Delirious with fatigue and emotional pain, Jason David called his mother to say he wanted to put a gun to his head, just to end the heartbreak of seeing his son suffer. His mother convinced him to not give up.

David turned to something he had seen on television: medical marijuana.

On June 4, 2011, David gave his son marijuana. For the first time since Jayden was 4 months old, the boy went through an entire day without a seizure.

“Instead of medical marijuana, this is miracle marijuana,” said David, holding up a jam jar full of liquefied and cooled cannabis.”

More: http://www.cnn.com/2012/12/10/health/medical-marijuana-child/

Children with epilepsy need medical marijuana

“Medical marijuana shouldn’t be for ‘adults only’.

My 9-year-old daughter has Aicardi syndrome, a rare genetic disorder that causes extremely hard-to-control seizures, debilitation, disability and early mortality. She began having seizures at three months of age, and since that time has had multiple seizures every day, with rare exception — probably to the tune of nearly 200,000 seizures in her lifetime…

She is one of the 3 million Americans who have epilepsy, and one of the 40 percent whose seizures cannot be controlled by anti-seizure drugs. She has tried 10 anti-seizure medications as well as a high-protein/low-carbohydrate diet called the ketogenic diet; she takes three anti-seizure medications at once and has a vagus nerve stimulator implant that sends mild electrical pulses to the brain. These drugs help her, but she nonetheless experiences an average of three seizures every day. Moreover, the medications cause persistent side effects that negatively impact her quality of life, particularly her gastrointestinal, bone, dental, cognitive and mental health.

The Illinois Senate Executive Committee recently voted, 10-5, to move the House-passed medical marijuana legislation to the Senate for a vote. The bill is expected to pass, and though Gov. Pat Quinn has not committed to signing it, the general expectation is that the bill will become law. This should be received as great news for the many people with “debilitating” conditions that the bill is supposed to help — people for whom medical science has documented real, measurable and safe outcomes of the controlled use of cannabis or its component of chemical compounds.

It’s too bad that the legislature has ignored the medical needs of some of the most debilitated, and most vulnerable, patients in the state: children with epilepsy.

Imagine her father’s and my reaction upon learning that the legislature, in its concern not to send a “message” to kids that it is safe to smoke marijuana, decided that kids like ours, for whom medical cannabis has the potential to be as safe and effective as typical anti-seizure drugs, should be excluded from the benefits of this new law.

They have done so, I hope, only out of ignorance…

There is no likelihood that my daughter will become a drug addict from using a compound within cannabis in a medically controlled setting. There is, however, a good chance that participation in a controlled study of these compounds could open the door to new treatments for her, and the many children like her, who desperately need medical innovation to save or improve their lives.”

More: http://articles.chicagotribune.com/2013-05-15/opinion/ct-oped-0515-marijuana-20130515_1_dravet-seizures-medical-cannabis